“Openness in government strengthens our democracy, promotes the delivery of efficient and effective services to the public, and contributes to economic growth.”—President Barack Obama’s Executive Order - Making Open and Machine Readable the New Default for Government Information (May 9, 2013)

MFIA represents clients attempting to make government more transparent through increased access to government data. Our current cases include:

Crawford v. New York City Department of Information, Technology and Telecommunications, Case Nos. 104275/2012 and 157002/2015 (N.Y. Sup.)
MFIA represents Harvard Law Professor Susan Crawford as she attempts to identify which areas of New York City are most underserved by the City’s current broadband infrastructure and to determine how well the City is fulfilling its mandate to bring high-speed Internet access to lower-income neighborhoods.

Treatment Action Group and Global Health Justice Partnership v. Food and Drug Administration and Department of Health and Human Services, 3:15-cv-00976-VAB (D. Conn.)
MFIA represents the Global Health Justice Partnership (GHJP) and Treatment Action Group (TAG), non-profit organizations committed to advancing public health and encouraging open access to clinical trial data, in a FOIA lawsuit to obtain the raw data FDA relied upon during its approval of the latest generation of hepatitis C (HCV) drugs.


In September 2016, the FDA approved eteplirsen, a new treatment for Duchenne muscular dystrophy, a previously-untreatable fatal childhood disease. Eteplirsen received accelerated approval, which is available for drugs treating “serious or life-threatening diseases” that provide “meaningful” benefit over existing therapies. Sarepta satisfied FDA’s standard using a twelve-patient clinical trial and the surrogate endpoint of dystrophin production.

Seife v. HHS

For a list of previous matters, please see the MFIA Archive